This study adopts a multicenter, randomized, double-blind, placebo-parallel controlled design to evaluate the efficacy and safety of L47 in the treatment of chronic hepatitis D.
A total of 150 subjects are planned to be enrolled. After passing the screening, they will be randomly assigned to the L47 group or the placebo group at a ratio of 2:1, with liver cirrhosis and subjects' regional distribution as stratification factors. The two groups will receive hepratide (2.1 mg/day) or placebo, respectively. Upon completion of the 48-week double-blind treatment phase, all subjects in each group can enter the open-label treatment follow-up phase, where they may voluntarily choose to receive L47 (2.1 mg/day) treatment or undergo follow-up observation only, until week 144.
Subjects who discontinue treatment prematurely during the trial may also enter the open-label treatment follow-up phase.
An interim analysis will be conducted after the subjects complete 24 weeks of trial treatment, with the comprehensive response rate at week 24 as the primary endpoint. The analysis will be performed by an independent statistical team. And the interim analysis results will be reviewed by the Independent Data Monitoring Committee (IDMC) .
All subjects will complete the 48-week double-blind clinical trial. Throughout the entire study period, the safety of subjects will be closely monitored and evaluated, including the monitoring of adverse events (AEs) and other safety indicators.
Positive HBsAg or HBV DNA for at least 6 months (diagnosed as chronic hepatitis B), with stable nucleos(t)ide analogue (NA) treatment for ≥3 months prior to screening and documented HBV DNA suppression;
Positive anti-HDV antibody (IgG and/or IgM) and at least two quantifiable HDV RNA measurements ≥3 months apart, with quantifiable HDV RNA at enrollment;
1×ULN< ALT<10×ULN；
No plan for pregnancy within 2 years; female subjects must not be pregnant or lactating, and all subjects must agree to use effective contraception during treatment and for 3 months after the last dose;
Child-Pugh class C or Child-Pugh score ≥10;
History of severe decompensated liver disease, including moderate to severe ascites (grade 2 or 3), hepatic encephalopathy, gastrointestinal variceal bleeding, hepatorenal syndrome, etc., with an expected survival of less than 2 years;
History of severe cardiac disease (including unstable or uncontrolled heart disease within the past 6 months, or New York Heart Association [NYHA] functional class III-IV);
Uncontrolled epilepsy, severe psychiatric disorders, or a history of severe psychiatric disorders;
Parallel
Hepalatide 2.1mg
DrugContinuous treatment with hepalatide 2.1mg sc, qd, for 48 weeks
Placebo of Hepalatide
DrugContinuous treatment with placebo of hepalatide for 48 weeks
Proportion of subjects who achieved response
HDV RNA suppression (\< LLOQ) or a decrease of ≥ 2 log10 from baseline combined with ALT normalization
Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline
Proportion of subjects with a ≥ 2 log₁₀ decrease in HDV RNA from baseline and normalized ALT
Proportion of subjects with HDV RNA below the limit of detection (LOD)
Changes in HDV RNA relative to baseline
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
